GlassScriptPhysician profile
Stephanie Charles
NPI 1588012413
$10,274.63
in general payments reported to CMS, 2019-2025
33 companies · $3,152 in 2025
The $3,152 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $402 · 2022: $2,305 · 2023: $2,284 · 2024: $2,131 · 2025: $3,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,496 · Education: $71.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,496.25 |
| Education | $71.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,429.04 | 2021-2025 | Evenity, Prolia, Tepezza |
| Corcept Therapeutics | $1,259.83 | 2021-2025 | Korlym |
| Novo Nordisk INC | $1,112.56 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $976.66 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Mannkind Corporation | $712.73 | 2022-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $655.78 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $584.29 | 2022-2025 | Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $544.72 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $461.62 | 2021-2023 | Farxiga |
| Abbott Laboratories | $357.57 | 2023-2025 | Freestyle Libre |
| Medtronic, INC. | $344.94 | 2021-2025 | Minimed 780g |
| Recordati_rare_diseases_inc. | $328.91 | 2022-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $328.87 | 2022-2025 | Synthroid, Botox |
| Radius Health, INC. | $194.53 | 2024 | Tymlos |
| Ascendis Pharma Endocrinology INC | $142.25 | 2023-2025 | Yorvipath |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $111.39 | 2022-2025 | Unithroid |
| Alvogen INC | $103.82 | 2023-2024 | Teriparatide |
| Merck Sharp & Dohme LLC | $101.24 | 2021-2023 | Steglatro |
| Embecta Corp. | $90.84 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Pfizer INC. | $72.53 | 2023-2024 | |
| Ultragenyx Pharmaceutical INC. | $65.78 | 2022-2024 | Crysvita |
| Endo Pharmaceuticals INC. | $48.86 | 2021-2022 | |
| Glaxosmithkline, LLC. | $47.22 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $31.47 | 2023 | Nexletol |
| Averitas Pharma INC. | $30.15 | 2023 | Qutenza |
| Neurocrine Biosciences, INC. | $21.87 | 2025 | |
| Halozyme INC | $20.01 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.34 | 2024 | Strensiq |
| Horizon Therapeutics Plc | $16.09 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.86 | 2022 | |
| Ibsa Pharma INC. | $14.95 | 2023 | Tirosint, Licart |
| Acerus Pharmaceuticals Corporation | $14.54 | 2022 | |
| Currax Pharmaceuticals LLC | $14.37 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.